One of the new drugs is Xuriden, a small molecule from Wellstat Therapeutics that treats an ultrarare disease called hereditary orotic aciduria. By the time Xuriden was approved last September, Wellstat had been working with its active ingredient, uridine triacetate, for close to 15 years. That’s a long road, but not out of the ordinary.
by Michael McCoy, Ann M. Thayer, Rick Mullin |
April 04, 2016